A Phase II Study of Docetaxel in Patients with Relapsed and Refractory Ewing's Tumours
Purpose. The prognosis for patients with Ewing's tumours who have metastases at presentation or who are refractory to standard chemotherapy regimens remains poor. There is therefore a need to evaluate the role of new agents. This report describes the initial results of a prospective phase II tr...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2003-01-01
|
| Series: | Sarcoma |
| Online Access: | http://dx.doi.org/10.1080/1357714031000114192 |